Lpath Awarded $1.45 Million Grant

Lpath Awarded $1.45 Million Grant

Lpath, Inc. (NASDAQ: LPTN) share price surged over 43% to $0.91 on nearly 10 Million shares traded after announcing the Company has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP), an agency of the U.S. Department of Defense (DoD). Lpath has developed three drug candidates, has advanced all three into clinical trials, and built evidence to support its approach of targeting bioactive lipids to treat a wide range of diseases. The grant will support the study of Lpathomab for the treatment of neuropathic pain associated with traumatic brain injury.

Related posts